EGFR (Ab-1172) Antibody

What is EGFR (Ab-1172) Antibody and what epitope does it recognize?

EGFR (Ab-1172) Antibody is a rabbit polyclonal antibody that recognizes the region surrounding tyrosine 1172 in the human EGFR protein. Specifically, it targets a synthesized non-phosphopeptide derived from human EGFR with the sequence P-D-Y-Q-Q (amino acids 1170-1174) . This antibody detects endogenous levels of total EGFR protein regardless of phosphorylation status at this site . It should not be confused with phospho-specific antibodies that only recognize EGFR when phosphorylated at Y1172.

The antibody is affinity-purified using epitope-specific immunogen chromatography, ensuring high specificity for its target . For researchers investigating total EGFR protein levels rather than specific phosphorylation events, this antibody provides reliable detection across multiple experimental platforms.

What is the recommended methodology for optimizing Western blot protocols with EGFR (Ab-1172) Antibody?

For optimal Western blot results with EGFR (Ab-1172) Antibody, follow this methodological approach:

• Protein extraction: Use cell lysis buffers containing phosphatase inhibitors (especially when studying signaling pathways)

• Protein loading: Load 20-40 μg of total protein per lane

• Separation: Use 8-10% SDS-PAGE gels to properly resolve the 175 kDa EGFR protein

• Transfer: Employ semi-dry or wet transfer to PVDF membranes

• Blocking: Block with 5% non-fat milk in TTBS for 1 hour at room temperature

• Primary antibody: Dilute EGFR (Ab-1172) Antibody 1:500-1:1000 in 5% milk/TTBS solution

• Incubation: Incubate overnight at 4°C with gentle rocking

• Secondary antibody: Use HRP-conjugated anti-rabbit IgG at 1:5000 dilution

• Detection: Employ enhanced chemiluminescence (ECL) for visualization

Expected result: A specific band at approximately 175 kDa corresponding to EGFR . A431 cells (high EGFR expression) serve as an excellent positive control, while MCF-7 cells can function as a negative control .

What species reactivity has been validated for EGFR (Ab-1172) Antibody?

EGFR (Ab-1172) Antibody has been experimentally validated for the following species:

When working with other species, preliminary validation experiments are strongly recommended as cross-reactivity has not been comprehensively examined across all mammalian species .

How can researchers troubleshoot non-specific bands or weak signals when using EGFR (Ab-1172) Antibody?

Non-specific bands and weak signals are common challenges when working with EGFR antibodies. Here's a systematic approach to troubleshooting:

For non-specific bands:

• Increase blocking time to 2 hours using 5% milk in TTBS

• Include 0.1% Tween-20 in all washing buffers

• Use freshly prepared samples with protease inhibitors

• For phospho-detection, ensure phosphatase inhibitors are present

• Try alternative blocking agents (BSA instead of milk) if phospho-proteins are the target

• Decrease primary antibody concentration to 1:2000 or higher

For weak signals:

• Increase protein loading to 50-75 μg per lane

• Extend primary antibody incubation to 24-48 hours at 4°C

• Decrease antibody dilution to 1:250-1:500

• Use enhanced sensitivity detection reagents

• Ensure your positive control (e.g., A431 cell lysate) is generating appropriate signals

• Try signal amplification systems such as biotin-streptavidin

When analyzing phosphorylation-dependent events, compare EGF-stimulated samples (e.g., A431 cells treated with 100 ng/ml EGF for 5 minutes) with unstimulated controls to confirm antibody functionality .

What experimental considerations are essential when using EGFR (Ab-1172) Antibody for immunohistochemistry?

When employing EGFR (Ab-1172) Antibody for immunohistochemistry (IHC), consider these methodological details:

• Tissue preparation:

  • Formalin-fixed paraffin-embedded (FFPE) sections (4-6 μm thickness)

  • Antigen retrieval is crucial: use citrate buffer (pH 6.0) at 95-100°C for 20 minutes

• Antibody optimization:

  • Initial dilution range: 1:100 to 1:500

  • Incubation: Overnight at 4°C in a humidified chamber

  • Include appropriate controls: breast carcinoma tissue as positive control

• Detection system:

  • Use polymer-based detection systems for enhanced sensitivity

  • DAB (3,3'-diaminobenzidine) is recommended as the chromogen

  • Counterstain nuclei with hematoxylin

• Validation method:

  • Always run a blocking peptide control (pre-incubate antibody with immunizing peptide)

  • Compare with alternative EGFR antibody clones

• Interpretation:

  • EGFR typically shows membrane localization

  • Assess both staining intensity and percentage of positive cells

  • Document subcellular localization patterns

When analyzing IHC results, remember that EGFR expression may be heterogeneous within tumors and that cytoplasmic versus membrane staining may have different biological and clinical significance .

How can EGFR (Ab-1172) Antibody be used to investigate EGFR's role in cancer cell invasion mechanisms?

EGFR plays a critical role in cancer cell invasion, and EGFR (Ab-1172) Antibody can be utilized to investigate these mechanisms through several methodological approaches:

• Co-immunoprecipitation studies:

  • Use EGFR (Ab-1172) Antibody (10 μl per reaction) with 1 mg of cell lysate

  • Add 25 μl of Protein A-agarose beads and rotate overnight at 4°C

  • Wash 3 times with lysis buffer and analyze by SDS-PAGE

  • Probe for invasion-related binding partners like STAT3, which is implicated in EGFR-driven invasion

• Invasion assay correlation studies:

  • Perform Matrigel invasion assays with cancer cell lines

  • Process parallel samples for EGFR expression/activation analysis

  • Correlate invasion capacity with EGFR levels detected by EGFR (Ab-1172) Antibody

  • Compare with phospho-specific antibodies to determine activation-dependence

• EGFR isoform analysis:

  • Combine with RT-PCR to detect alternative splicing variants

  • Use EGFR (Ab-1172) Antibody to determine if novel isoforms like EGFRvA are detected

  • EGFRvA has been shown to confer increased invasiveness compared to wild-type EGFR

• Downstream signaling analysis:

  • Combine with antibodies against invasion-related signaling molecules

  • Monitor STAT3 activation, which upregulates HB-EGF creating a positive feedback loop

  • Track AKT and ERK activation in relation to EGFR levels

Research has shown that certain EGFR isoforms like EGFRvA relate more closely to histopathologic grade and poor prognosis in patients with glioma . Using EGFR (Ab-1172) Antibody in combination with isoform-specific detection methods can provide insights into the molecular mechanisms of cancer invasion.

How does EGFR phosphorylation at Y1172 affect downstream signaling pathways, and how can this be studied?

EGFR phosphorylation at Y1172 (pY1172) is a critical regulatory event in EGFR signaling. To comprehensively study its effects:

• Comparative phosphorylation studies:

  • Use both EGFR (Ab-1172) Antibody and phospho-specific anti-EGFR (pY1172) antibodies

  • Stimulate cells with varying EGF concentrations (1-100 ng/ml)

  • Generate time-course data (0-60 minutes post-stimulation)

  • Compare phosphorylation kinetics at Y1172 versus other tyrosine sites

• Mutational analysis approach:

  • Generate Y1172F EGFR mutants to prevent phosphorylation

  • Compare signaling outputs between wild-type and mutant EGFR

  • Analyze differences in biological responses (proliferation, migration, survival)

• Signaling pathway analysis:

  • Monitor activation of downstream pathways including:

    • STAT3 pathway (implicated in EGFRvA-mediated invasion)

    • AKT pathway (cell survival)

    • ERK pathway (proliferation)

  • Use phospho-specific antibodies against p-AKT, p-ERK, p-STAT3

• Inhibitor studies:

  • Apply EGFR tyrosine kinase inhibitors (TKIs) at varying concentrations

  • Monitor Y1172 phosphorylation status versus other sites

  • Correlate with inhibition of downstream signaling events

Data from such experiments typically show that Y1172 phosphorylation contributes to recruitment of specific signaling adaptors, with phosphorylation occurring rapidly (within 5 minutes) after EGF stimulation in A431 and HeLa cells . The presence of a positive feedback loop involving STAT3 and HB-EGF further reinforces signaling through this site .

What methodologies can be employed to study EGFR heterodimerization with other ErbB family members?

EGFR heterodimerization with other ErbB family receptors is a critical regulatory mechanism. EGFR (Ab-1172) Antibody can be employed in several approaches to study this phenomenon:

• Co-immunoprecipitation strategy:

  • Immunoprecipitate with EGFR (Ab-1172) Antibody

  • Western blot for other ErbB family members (ErbB2/HER2, ErbB3, ErbB4)

  • Analyze changes in dimerization patterns after ligand stimulation

  • Compare results with reverse co-IPs using antibodies against other ErbB receptors

• Proximity ligation assay (PLA):

  • Use EGFR (Ab-1172) Antibody paired with antibodies against other ErbB receptors

  • Quantify fluorescent spots indicating <40 nm proximity

  • Compare different cell types and conditions

  • Analyze subcellular localization of dimers

• FRET/BRET analysis:

  • Tag EGFR and binding partners with appropriate fluorophores

  • Use antibody-based detection of endogenous proteins

  • Measure energy transfer as indicator of dimerization

  • Compare results with biochemical approaches

• Bispecific antibody comparison:

  • Compare findings with studies using bispecific antibodies like XGFR*

  • XGFR* targets both IGF-IR and EGFR simultaneously, providing insights into receptor cooperation

Research using these approaches has demonstrated that EGFR forms heterodimers with varying affinities depending on ligand stimulation, with EGF promoting EGFR-HER2 dimers while HB-EGF may favor different partnership patterns . The bispecific antibody XGFR* has shown tumor suppressive activity in xenograft models by targeting both IGF-IR and EGFR, highlighting the therapeutic potential of targeting receptor dimerization .

How does EGFR (Ab-1172) Antibody compare with phospho-specific EGFR antibodies in research applications?

When choosing between EGFR (Ab-1172) Antibody and phospho-specific alternatives, consider these comparative aspects:

For comprehensive signaling studies, using both antibodies in parallel provides complementary information: EGFR (Ab-1172) Antibody reveals total receptor levels while phospho-specific antibodies determine the proportion in an activated state. This dual approach is particularly valuable when studying drug responses, where changes in phosphorylation may occur without alterations in total protein levels .

What are the critical methodological differences when using EGFR (Ab-1172) Antibody versus antibodies targeting alternative EGFR epitopes?

Different EGFR antibodies target distinct epitopes, necessitating methodological adjustments:

• Epitope accessibility considerations:

  • EGFR (Ab-1172) Antibody targets the C-terminal region (aa 1170-1174)

  • Antibodies targeting extracellular domains may require different fixation methods

  • Membrane permeabilization is critical for EGFR (Ab-1172) Antibody in IF applications

  • Antigen retrieval methods may need optimization based on epitope location

• Conformation-dependent detection:

  • C-terminal antibodies like EGFR (Ab-1172) may be affected by protein-protein interactions

  • Antibodies against extracellular domains can detect receptor under native conditions

  • Denaturation in SDS-PAGE may affect epitope recognition differently

• Isoform detection variations:

  • EGFR (Ab-1172) Antibody may detect multiple isoforms including potential variants like EGFRvA

  • N-terminal antibodies would detect all isoforms with intact N-terminus

  • Domain-specific antibodies provide information about structural variations

• Cross-reactivity profiles:

  • EGFR (Ab-1172) Antibody is validated for human, mouse, and rat

  • Antibodies targeting more conserved domains may show broader species reactivity

  • Epitope conservation analysis is essential when working with non-validated species

When designing experiments to study novel EGFR isoforms like EGFRvA, which substitutes a Ser/Thr-rich peptide for part of the C-terminal regulatory domain, epitope positioning becomes critical . Using multiple antibodies targeting different EGFR regions provides more comprehensive information about receptor structure, processing, and potential isoform expression.

How can EGFR (Ab-1172) Antibody be used to investigate resistance mechanisms to EGFR-targeted therapies?

Resistance to EGFR-targeted therapies presents a significant clinical challenge. EGFR (Ab-1172) Antibody can be employed to investigate resistance mechanisms through these methodological approaches:

• Expression-activation correlation studies:

  • Compare total EGFR levels (using EGFR Ab-1172) with phosphorylation status

  • Analyze resistant versus sensitive cell lines/tissues

  • Determine if resistance correlates with expression-activation discordance

  • Track changes during treatment time courses

• EGFR isoform profiling:

  • Assess whether resistant cells express alternative EGFR isoforms like EGFRvA

  • Compare isoform expression patterns between responsive and resistant samples

  • Correlate findings with response to EGFR-targeting drugs

  • EGFRvA has been linked to increased invasiveness and poor prognosis

• Pathway compensation analysis:

  • Use EGFR (Ab-1172) Antibody in combination with antibodies against:

    • Alternative RTKs (HER2, MET, IGF-1R)

    • Downstream effectors (AKT, ERK, STAT3)

  • Identify activation of bypass pathways despite EGFR inhibition

  • Compare with bispecific antibody approaches targeting multiple receptors

• Receptor trafficking alterations:

  • Employ immunofluorescence with EGFR (Ab-1172) Antibody

  • Track changes in receptor localization and internalization kinetics

  • Compare endocytic trafficking between sensitive and resistant cells

  • Correlate with therapeutic response

Research has shown that resistance often develops through alternative pathway activation while maintaining EGFR expression, or through expression of variant forms like EGFRvA that may alter signaling properties . Bispecific antibodies targeting both IGF-IR and EGFR represent one approach to overcoming resistance by simultaneously blocking multiple receptors .

What strategies can be employed to study EGFR's role in the tumor microenvironment using EGFR (Ab-1172) Antibody?

To investigate EGFR's role in the tumor microenvironment (TME), consider these methodological approaches:

• Multi-label immunohistochemistry:

  • Use EGFR (Ab-1172) Antibody in conjunction with markers for:

    • Cancer-associated fibroblasts (α-SMA, FAP)

    • Immune cells (CD4, CD8, CD68)

    • Vascular markers (CD31)

  • Employ multi-spectral imaging to analyze spatial relationships

  • Quantify EGFR expression relative to stromal components

• Co-culture experimental systems:

  • Establish cancer cell and stromal cell co-cultures

  • Apply EGFR (Ab-1172) Antibody to track receptor expression changes

  • Compare homotypic versus heterotypic culture conditions

  • Analyze how stromal factors affect EGFR expression/phosphorylation

• 3D organoid/spheroid analysis:

  • Develop tumor organoids with stromal components

  • Section and stain with EGFR (Ab-1172) Antibody

  • Compare EGFR distribution between 2D and 3D culture systems

  • Correlate with invasion capacity and growth characteristics

• Secretome analysis in relation to EGFR expression:

  • Collect conditioned media from tumor/stromal co-cultures

  • Analyze secreted factors (growth factors, cytokines)

  • Correlate findings with EGFR expression/activation patterns

  • Focus on HB-EGF, which has been implicated in EGFR-driven invasion

Microenvironmental interactions may regulate the expression of different EGFR isoforms, including EGFRvA, which has been associated with increased invasiveness . The presence of HB-EGF in the tumor microenvironment may establish positive feedback loops that reinforce EGFR signaling through phosphorylation at sites like Y1172, potentially driving more aggressive phenotypes .

How can researchers employ EGFR (Ab-1172) Antibody to investigate post-translational modifications beyond phosphorylation?

While phosphorylation is the most studied EGFR modification, other post-translational modifications (PTMs) significantly impact receptor function. To investigate these using EGFR (Ab-1172) Antibody:

• Sequential immunoprecipitation approach:

  • First IP: Use EGFR (Ab-1172) Antibody to pull down total EGFR

  • Second analysis: Probe for specific PTMs including:

    • Ubiquitination (affects degradation)

    • Glycosylation (impacts folding/trafficking)

    • Acetylation (regulates signaling)

    • SUMOylation (alters localization/function)

  • Compare PTM patterns under various conditions

• Mass spectrometry workflow:

  • Immunoprecipitate EGFR using EGFR (Ab-1172) Antibody

  • Process samples for LC-MS/MS analysis

  • Map identified PTMs to receptor structure

  • Quantify changes in modification state after treatments

• Inhibitor studies:

  • Apply specific PTM enzyme inhibitors (deubiquitinases, glycosidases)

  • Track changes in EGFR molecular weight/banding pattern

  • Correlate with functional outcomes (signaling, trafficking)

  • Compare results across different cell types/conditions

• Site-directed mutagenesis validation:

  • Generate EGFR mutants at potential PTM sites

  • Express in relevant cellular contexts

  • Compare PTM patterns using EGFR (Ab-1172) Antibody

  • Correlate with functional changes in receptor behavior

These approaches reveal how EGFR function is regulated by a complex interplay of PTMs beyond phosphorylation. For example, ubiquitination patterns affect receptor degradation kinetics, while glycosylation impacts folding, trafficking and ligand binding properties. The C-terminal region of EGFR, where the Ab-1172 epitope resides, is particularly rich in regulatory PTM sites that modulate signaling outcomes .